

## SCIENTIFIC PROGRAM

**FRIDAY, JUNE 26, 2026**

**Panel: Therapeutic Implications of Molecular Heterogeneity**

**Introduction: MIB Agents Junior Advisory Member**

**Moderator: Anand Patel, MD, PhD | St. Jude Children's Research Hospital**

Weisong Zhao, MD, PhD candidate | Shanghai Bone Tumor Institute, Shanghai General Hospital  
*Deciphering Complex Oncogenic Amplicons in Osteosarcoma*

Ilanthe van Belzen, PhD | EMBL-EBI (European Bioinformatics Institute)  
*Unravelling the phenotypic and clinical impact of complex genomic rearrangements in osteosarcoma*

Yanding Zhao, PhD | Mohamed bin Zayed University of Artificial Intelligence (MBZUAI)  
*Distinct patterns of chromosomal instability fuel osteosarcoma progression and influence patient outcomes*

Andrew Clugston, PhD | University of California, San Francisco  
*Identifying tumor-specific vulnerabilities by mapping oncogenic structural variation in osteosarcoma*

Corey Weistuch, PhD | Memorial Sloan Kettering Cancer Center  
*Implementing personalized, adaptive therapies in osteosarcoma*

Amy LeBlanc, DVM, DACVIM | NIH/National Cancer Institute  
*Canine osteosarcoma multiomic profiling provides new insights and therapeutic opportunities for dogs and humans*

**Panel: From Crosstalk to Targets: Exploiting the Tumor Microenvironment**

**Introduction: MIB Agents Junior Advisory Member**

**Moderator: Dan Regan, DVM, PhD | Flint Animal Cancer Center, Colorado State University**


Amy Gross, MS | Nationwide Children's Hospital  
*Metastasis-Initiating Osteosarcoma Cells Shape Lung Microenvironment Through Paracrine Signaling*

Rebecca Makii, MS, DVM | Colorado State University  
*Understanding the metastatic osteosarcoma tumor microenvironment using cross-species spatial transcriptomics*

Fatemeh Yazarlou, PhD | Nationwide Children's Hospital  
*Cell-type-resolved mapping of tumor-specific kinase networks in the osteosarcoma metastatic niche predicts effective Tyrosine kinase inhibitors (TKIs) therapy*

Rebecca Nance-Richey, PhD | University of Florida  
*Spatial Transcriptomic Sequencing of Canine Osteosarcoma Reveals Immune Niches in the Tumor Microenvironment*

Yogesh Budhathoki, PhD Candidate | Nationwide Children's Hospital  
*Integrative Single-cell and Spatial Transcriptomic Analysis of Osteosarcoma Reveals Conserved and Distinct Ecosystems Across Sites and Species*



## SCIENTIFIC PROGRAM

**Update: Break Through Cancer - Defying Osteosarcoma Team Lab**

Katie Janeway, MD, MMSc | Dana-Farber Cancer Institute

**OutSmarting Osteosarcoma 2026 Awards Presentation**

**Moderators: Christina Ip-Toma | MIB Agents and Matteo Trucco, MD | Cleveland Clinic**

TBD

**Panel: Evolving Strategies for Local Control**

**Introduction: MIB Agents Junior Advisory Member**

**Moderator: Thomas Scharschmidt, MD | Nationwide Children's Hospital**

Anna R. Cooper, MD, MPH | Montefiore Einstein

*Functional Outcomes After Upfront Surgery for Osteosarcoma: A Pilot Study*

Daniel Ebner, MD, MPH | Mayo Clinic

*High LET Radiotherapy for Osteosarcoma*

Theresa Busch, PhD | University of Pennsylvania


*FLASH Ultra-high Dose Rate Radiotherapy in the Treatment of Osteosarcoma*

Aleyna La Croix, MS, PhD Student | Dartmouth College

*MXene-Integrated Scaffolds for Localized Tumor Treating Field Delivery in Osteosarcoma*

Erin S. Murphy, MD | Cleveland Clinic

*Sarcoma SBRT Task Force*



## SCIENTIFIC PROGRAM

### **Panel: Expanding Immunotherapy Approaches in Osteosarcoma**

**Introduction: MIB Agents Junior Advisory Member**

**Moderator: Nancy Gordon, MD | The University of Texas MD Anderson Cancer Center**

Joseph Skeate, PhD | University of Minnesota

*Next generation dual-CAR  $\gamma\delta$  T cells for the treatment of pediatric osteosarcoma*

Ali Cihan, PhD | Memorial Sloan Kettering Cancer Center

*Development of EPHA2 CAR T Cell Therapy for Pediatric Osteosarcoma*

William Kisseberth, DVM, PhD | The Ohio State University

*Phase I evaluation of adjuvant cell therapy with TGF beta-resistant NK cells in dogs with osteosarcoma*

Jeffrey Bryan, DVM, MS, PhD | University of Missouri

*Improving Outcomes in Osteosarcoma: Vaccine-enhanced Adoptive Cell Therapy After Short-Course Chemotherapy in a Naturally Occurring Canine Model*

Julie Tomolonis, MD, PhD | Nationwide Children's Hospital

*Dual targeting of osteosarcoma and stromal microenvironment using FAP-directed immunotherapeutics*

### **SATURDAY, JUNE 27, 2026**

### **Panel: Molecular Pathways and Therapeutic Vulnerabilities**

**Introduction: MIB Agents Junior Advisory Member**

**Moderator: Ryan D. Roberts, MD, PhD | Nationwide Children's Hospital/The Ohio State University**

Pankita H. Pandya, PhD | Indiana University School of Medicine

*BET Bromodomain Targeting Induces TXNIP, DNA Damage, and Potentiates Salvage Chemotherapy in Preclinical Models of Osteosarcoma*

Emily Seiden, PhD | University of Michigan

*MYC Modulation Alters Metastasis in High-Risk Osteosarcoma*

Janeala Morsby, PhD | St. Jude Children's Research Hospital


*Potentiating Cohesin Collapse With PARP Plus ATM Inhibition In Pediatric Osteosarcoma*

Alexander Davies, DVM, PhD | Knight Cancer Institute, Oregon Health and Science University

*Decoding niche organization patterns and signaling dynamics that underlie osteosarcoma cell fates*

H. David Ulmert, MD, PhD | University of California, Los Angeles

*Developing LRRRC15-Targeted Radiotheranostics to Ablate Aggressive Osteosarcoma and Reprogram TGF $\beta$ -Driven Immunoresistance*



## SCIENTIFIC PROGRAM

### **Panel: Addressing Chemoresistance in Osteosarcoma**

**Introduction: MIB Agents Junior Advisory Member**

**Moderator: Livia Garzia, PhD | McGill University**

Surabhi Menon, MD | Memorial Sloan Kettering Cancer Center/ New York Presbyterian Weill Cornell  
*Proteo-genomic profiling of chemotherapy persistence in Osteosarcoma PDX models*

Zachary Burke, MD | Cleveland Clinic  
*Evolving toward precision oncology: Leveraging collateral drug responses for personalized second-line osteosarcoma treatment*

Laurie Graves, MD | Duke University  
*Eco-Evolutionary Strategies for Extinction-Based Therapy in Osteosarcoma*

Aafrin Pettiwala, PhD | University of California, San Francisco  
*Tracking tumor clonal dynamics in response to chemotherapy in metastatic osteosarcoma using molecular barcoding*

Ram Rao, MD, PhD | Seattle Children's Research Institute  
*Extracellular Matrix Density Mediates Osteosarcoma Phenotype*

### **Panel: Novel Therapeutic Modalities and Delivery Strategies**

**Introduction: MIB Agents Junior Advisory Member**

**Moderator: Richard Gorlick, MD | The University of Texas MD Anderson Cancer Center**


Jay Sarthy, MD, PhD | Seattle Children's Research Institute  
*Epigenetic Targeting of Translation in Osteosarcoma*

Jonathan Gill, MD | The University of Texas MD Anderson Cancer Center  
*Development of Antibody-Drug Conjugates in Osteosarcoma*

Sagar Bhattacharya, PhD | University of California, San Francisco  
*De novo design of radium-binding proteins*

Iman Mevaa, PhD Candidate | Purdue University  
*MicroRNA for Major Impact: Ligand-Mediated Delivery of Tumor-Suppressive miRNA-34a to Treat Osteosarcoma*

Masahiro Hitomi, MD, PhD | Cleveland Clinic  
*Enhancing osteosarcoma immunotargeting efficacy by combination therapy*



## SCIENTIFIC PROGRAM

### **Panel: Patient Panel**

**Introduction: MIB Agents Junior Advisory Member**

**Moderator: Matthew Dietz, DO, MSED | Primary Children's Hospital, University of Utah**

MIB Junior Advisory Board Panelists

### **Update: CURE-OS - Collaborative Understanding of the Range and Evolution of Osteosarcoma Single-cells**

Jovana Pavisic, MD | Memorial Sloan Kettering Cancer Center

*Overview, Background, Goals*

Dan Regan, DVM, PhD | Colorado State University

*Decoding the Osteosarcoma Tumor Microenvironment: A Review and Outlook for Clinical Translation*

Anand Patel, MD, PhD | St. Jude Children's Research Hospital

*A roadmap for osteosarcoma: intratumoral heterogeneity*

Corey Weistuch, PhD | Memorial Sloan Kettering Cancer Center

*Next Steps*

### **Panel: Clinical Trials**

**Introduction: MIB Agents Junior Advisory Member**

**Moderator: Sarah Whittle, MD | St. Jude Children's Research Hospital**

Amy E. Armstrong, MD | Washington University in St. Louis

*Open-label, cohort-sequential dose-escalation and dose-confirmation Phase 1/2 clinical trial to evaluate the safety and efficacy of domatinostat in combination with sirolimus in adolescents and adults with relapsed, refractory sarcoma and osteosarcoma*

Michelle Choe, MD | Fred Hutch Cancer Center/Seattle Children's Hospital

*FIERCe: FOLR1 Immune Effector Cell Therapy against Advanced Osteosarcoma*

Noah Federman, MD | University of California, Los Angeles

*A Phase 1/2 Study to Evaluate LNTH-2403, a LRRC15-targeted <sup>177</sup>Lutetium-labeled Monoclonal Antibody, in Participants With Relapsed / Refractory Osteosarcoma: A trial in progress*

Alice Lee, MD | Children's Hospital at Montefiore

*DFMO Maintenance for patients with relapsed/refractory Ewing sarcoma or Osteosarcoma*

Filemon Dela Cruz, MD | Memorial Sloan Kettering Cancer Center

*OstEvo: A Strategy-Based Clinical Trial Advancing New Treatment Strategies for Metastatic and Relapsed Osteosarcoma*